|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.075 AUD | -3.85% |
|
0.00% | +8.70% |
| Apr. 17 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
| Apr. 17 | Neurotech International Completes AU$10 Million Capital Raise | MT |
Neurotech International Limited reported earnings results for the half year ended December 31, 2022. For the half year, the company reported sales was AUD 0.002988 million compared to AUD 0.047732 million a year ago. Net loss was AUD 3.54 million compared to AUD 1.81 million a year ago.
Basic loss per share from continuing operations was AUD 0.0048 compared to AUD 0.0026 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +8.70% | 53.05M | |
| -11.41% | 2.95B | |
| +2.35% | 190M | |
| -14.72% | 84.22M |
NEUROTECH INTERNATIONAL LIMITED 
